Transcript Slide 1
About the Speaker: Program in Emerging Infectious Diseases (EID) “Henipavirus Envelope Glycoproteins and Receptor Interactions: Structure, Function, and Therapeutic Targets” By Dr Christopher C. Broder, Ph.D. Professor, Department of Microbiology and Immunology Director, Emerging Infectious Diseases Graduate Program Uniformed Services University, Department of Defense, Bethesda Abstract : Hendra and Nipah are viral zoonoses first recognized in the mid and late 1990’s and now comprise the genus Henipavirus within the paramyxovirus family. Their broad species tropism together with their capacity to cause severe and often fatal disease in both humans and animals make them significant transboundary biosecurity threats. Functional and structural studies on the Hendra and Nipah, and now also Cedar virus, attachment G and fusion F envelope glycoprotein have led to new models of protein receptor using paramyxovirus entry. These efforts have also led to the development of advanced and very effective active and passive immunization strategies to prevent and treat Hendra and Nipah virus infection and disease. All are welcome Date : July 5, 2013 (Friday) Time : 4.00 – 5.00 pm Host : Professor Linfa (Lin-Fa) WANG, PhD FTSE, Program Director Program in Emerging Infectious Diseases Venue : Duke-NUS, Amphitheatre, 2nd Floor B.S. (83’) M.S. (85’) Florida Tech; Ph.D. (89’) University of Florida (Thesis: discovery and characterization of a specific receptor for human plasmin on Group A Streptococci, the molecular-pathogenic model for the "flesheating streptococci"). 1989-96: Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, National Research Council Research Associate, and IRTA Fellow; 1996-present: Department of Microbiology and Immunology, Uniformed Services University (USU), Department of Defense, Bethesda, MD. 2005present: Professor, USU, and Director, Emerging Infectious Diseases Graduate Program. Editorial boards: Journal of Virology, Virology, Viruses, Pathogens, Virologica Sinica; member: American Society for Microbiology (ASM), American Association for the Advancement of Science (AAAS), American Society for Virology (ASV), Asia Pacific Society for Medical Virology (APSMV), American Society of Tropical Medicine and Hygiene (ASTMH). Current research programs focus on virushost cell interactions with an emphasis on vaccines and antibody therapeutics development for HIV and emerging viruses including Nipah and Hendra viruses and animal model development, Ebola and Marburg viruses, and bat Lyssavirus. Major research contributions include the model of distinct membrane fusion accessory factors as the basis for HIV-1 cell-type tropism in 1993, the discoveries of the CXCR4 (1996-Breakthrough of the Year, Science Magazine and the AAAS, Newcomb Cleveland Prize 97’) and the CCR5 HIV-1 coreceptors; development of the Hendra/Nipah soluble G glycoprotein subunit vaccine and antiviral human monoclonal antibodies against Nipah and Hendra viruses. Co-inventor of several issued and pending patents related to CXCR4, CCR5, HIV-1 gp140, paramyxovirus fusion inhibitors, soluble Hendra and Nipah virus G and F glycoproteins and antiviral human monoclonal antibody therapeutics, among others.